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Summary 
Testing of symptomatic persons for infection with SARS-CoV-2 is increasingly being used in health 
care settings in different countries. It is important to consider efficient ways to collect information 
that will allow us to understand the causes of the evolving COVID-19 pandemic. We propose two 
types of case-control studies that can be carried out jointly in test-settings for symptomatic persons.  
The first, the test-negative case-control design (TND) is the easiest to implement as it only demands 
collecting information about potential risk factors for COVID-19 from those symptomatic persons 
who are tested, some of which would already be collected routinely. The second, standard case-
control studies (CC) with population controls (ideally added onto a TND study), requires the 
collection of data on one or more population controls for each person who is tested in the test 
facilities, so that test-positives and test-negatives can each be compared with (their) population 
controls. We first summarize the TND and explain how to add it to large-scale testing of 
symptomatic persons. The TND will detect differences in risk factors between symptomatic persons 
who have COVID-19 (test-positives) and those who have other respiratory infections (test-
negatives). However, risk factors with effect sizes of equal magnitude for both COVID-19 and other 
respiratory infections will not be identified by the TND. Second, we therefore discuss how to also 
add population controls to compare with the test-positives and the test-negatives separately, 
yielding two additional case-control studies. We provide detailed examples of two very different 
types of population control groups: one composed of accompanying persons to the test facilities; the 
other drawn from existing country-wide health care databases. We also give suggestions for other 
types of population controls that might be most suitable in other situations. The combination of the 
test-negative design with the addition of population controls yields a triangulation approach that 
distinguishes between exposures that are risk factors for both COVID-19 and other respiratory 
infections, and exposures that are risk factors for just COVID-19, or just for other respiratory 
infections. Incorporating the test-negative design into on-going testing efforts is useful in itself, but it 
is even more useful with the addition of population controls.  
[354 WORDS]  
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Widespread testing is essential for monitoring the Coronavirus 2019 (COVID-19) pandemic.[1, 2] 
Most countries are focussing on testing persons with symptoms, since this maximises the chance of 
identifying patients with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infections. 
Ideally, this should be coupled with random/representative population testing to follow the 
epidemic in the population.[3] However, there is much that can be learnt about the causes of 
COVID-19, even if only symptomatic people are tested. Still more may be learnt by conducting 
formal test-negative design studies, with additional population controls, thus yielding three linked 
case-control studies. In this paper, we describe these study designs, and how they can enhance 
understanding of risk factors for symptomatic SARS-CoV-2 infection in the COVID-19 pandemic. 
Essence of the Test-Negative Case-control Design (TND) 
Test-negative case-control studies[4-9] are based on persons who undergo testing because they 
present with signs and symptoms that may point to a particular disease. The cases are those who 
test positive for the disease, and the controls are those who test negative - the latter will have 
another reason for their signs and symptoms, most likely another disease. [8] These ‘cases’ and 
‘controls’ usually come from a particular geographical population, although not everyone in a 
particular area may present for testing (and some people may come from outside of the area).  
TNDs involve comparing the odds of a given intervention (e.g. vaccine receipt) or a given risk factor 
(e.g., oral contraceptives) among symptomatic persons who test positive compared to those who 
test negative.  Given certain assumptions described in the literature,[8] it can produce effect 
estimates (odds ratios) which are generalizable to the general population. See APPENDIX A for more 
detail about these assumptions. The approach has most commonly been used for assessing vaccine 
effectiveness[4] or for identifying risk factors for antibiotic resistance,[5, 10] but has also been 
applied to estimate risk factors in circumstances in which diagnostic suspicion bias was suspected, 
for example in studies on oral contraceptives and venous thrombosis, and on aspirin use and Reye 
syndrome.[8]  
Test-negative designs are an expedient way to obtain quick answers to important questions. An 
additional advantage is that, by design, they protect against some forms of bias which are otherwise 
difficult to control. People who get tested for a disease will not be representative of all those who 
have the disease (unless everyone in the population is tested) - usually, they are more likely to have 
severe symptoms, and more likely to seek medical help. This help-seeking behaviour is in turn 
affected by many factors such as age, gender, socioeconomic status, access to health care, proximity 
to testing facilities, severity of symptoms, type of personality (degree of hypochondria), and in 
certain settings also insurance coverage. The idea of the test-negative design is that the same 
selective forces that lead individuals to be tested will operate on both those who test positive and 
those who test negative. Thus, there has been substantial discussion of this study design,[4-9] and it 
is generally agreed that it can produce valid effect estimates under the assumption that the 
selection forces are similar for the test-positives (the cases) and the test-negatives (the controls).  
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Reasons for considering the TND in the COVID-19 pandemic 
Given that large numbers of people are being tested in the population, additional insights into the 
risk factors for COVID-19 can be gained by collecting the same information on symptomatic 
individuals who test positive and those who test negative, i.e. by performing a test-negative case-
control study.   
Because the test-negatives belong to the same population (i.e. people who would come for testing if 
they had symptoms of COVID-19) as the test-positives, this may give timely and locally relevant 
insight into the causes of SARS-CoV-2 infection in different types of communities (urban, rural), in 
communities where there are many cases, as well as in communities where there are few cases. 
Direct comparisons of test-positives to test-negatives (comparison TND in Figures 1 and 2) can yield 
insight into specific risk factors for becoming infected and symptomatic with SARS-CoV-2: these may 
include age, sex, race/ethnicity, socioeconomic factors (e.g. income, education), occupational 
exposures (e.g. healthcare workers performing aerosol-generating procedures, delivery drivers, 
teachers), contact patterns (e.g. household exposure to confirmed case, crowding, travel histories, 
childcare responsibilities), geographic residence (e.g. urban versus rural), behavioural factors (e.g. 
shopping locations, smoking), medical risk factors (e.g. immunodeficiency), and genetic factors (from 
the swabs or blood sample taken for viral diagnosis, which will also contain human cells).  
It is not necessary that all test sites ask for all this information. Some of this information might 
already be routinely collected. If a sufficient number of test sites test large numbers of people, 
different types of additional information may be asked at different testing sites – so as not to burden 
the test sites and to be able to answer several questions at once, and to be able to adapt short 
questionnaires to evolving questions. Some risk factors may be immediately important for local 
decisions, others more widely or more theoretically. The data can be analysed just like any other 
case-control study, although additional consideration should be given to assessing various possible 
interpretation issues arising because both the cases and controls are drawn from a subgroup of the 
general population (see also APPENDIX A).[8] 
Critical reflections on the interpretation and feasibility of the TND in the COVID-19 pandemic 
As with any other TND study, there are several aspects which need to be considered critically. 
Most importantly, the TND involves a comparison between persons who test positive for SARS-CoV-
2 and persons who test negative but who have similar signs and symptoms. Therefore, the test-
negatives will have another reason for their similar signs and symptoms - most likely they will have 
another respiratory infection, by another virus. There will be some exposures (e.g. overcrowding), 
which increase the risks both of COVID-19 and of other respiratory infections. It follows that the TND 
can only identify those risk factors that are either totally distinct or clearly different in magnitude 
from the risk factors for illnesses that can manifest with similar symptoms.  So if, for example, living 
in crowded conditions equally increased the risks both of COVID-19 and of other respiratory 
infections, then the proportions living in crowded conditions would be similar in the test-positives 
and the test-negatives. On the other hand, if male sex was a risk factor for symptomatic SARS-CoV-2 
infection, but not for other respiratory infections, then more of the test-positives than the test-
negatives would be male.  
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A second concern is about the sensitivity and specificity of the tests used. Although RT-PCR testing 
has a high specificity for SARS-CoV-2, the sensitivity can vary in relation to the timing of symptom 
onset,[11, 12] the bodily fluid tested,[13] and the assay used.[14] So, there will be misclassification 
of cases and controls. This can be expected to be ‘non-differential’ (whether the test works correctly 
on a particular person is unrelated to exposures such as crowding). Such non-differential 
misclassification of exposure or disease is a known problem in case-control studies, and it usually 
results in bias of the effect estimate towards the null, i.e., an underestimation of effects. However, 
there is a major difference between the usual case-control study and the TND. In the usual 
population-based case-control study, the false-negatives remain part of the source population, and 
only a (small) fraction of them will be sampled and end up in the control group. The false-positives 
will be in the case group, but not all persons from the population will be tested for a particular 
disease: only those who present with signs and symptoms will be tested, and these have a higher 
prior than the general population, so the Predictive Positive Value of a test might be relatively good. 
In contrast, in the TND it is certain that at a particular test site all false-negatives will be included in 
the control group (the test negatives); and all false-positives will be included in the case group - since 
all persons tested at the test site will be in the study. This may lead to stronger misclassification and 
has most consequences in situations wherein the proportion of COVID-19 relative to other 
respiratory disease among the persons tested is either very high or very low. While there is an 
extensive literature on sensitivity analysis for standard case-control studies,[15, 16] which essentially 
involves making assumptions about how large this misclassification would be, these methods will 
have to be adapted to the TND situation. See APPENDIX B for further details.  
An additional reflection is about seasonality; it is not known at the time of writing how the incidence 
of SARS-CoV-2 infections over the calendar year will evolve. There is the possibility that other 
respiratory viruses such as influenza might disappear during summer,[11] whereas the SARS-CoV-2 
may continue to circulate; in that situation, there may not be sufficient test-negative controls.  
Adding standard case-control studies with a control group representing the underlying population 
As noted, a TND can potentially identify risk factors for COVID-19 that differ from those for other 
respiratory infections, either in kind or in magnitude, but will not identify risk factors that the test-
positives and test-negatives have in common. On the other hand, comparing test-positives with 
general population controls will tell us about risk factors for COVID-19, but does not tell us which 
factor is specific for SARS-CoV-2 rather than respiratory infections in general.  The ideal situation is 
to have both comparisons. This strategy has been advocated and applied as an extension of TNDs of 
antibiotic resistance.[5, 10]  
Below, we will outline two very different strategies to obtain population controls: first the use of 
‘accompanying persons’ (e.g., friends or household members) as ‘matched controls’, and second the 
use of a random sample from general population databases with country-wide health care and other 
registered information from that population. Additionally, in a separate section, we will briefly 
discuss other possibilities for choosing controls that might be more useful in a diversity of situations. 
Thereafter, we offer some critical reflections about the choice of population controls. Here we use 
the term ‘population controls’ to refer to any selection of controls from the source population which 
generated the cases – this can include matched or unmatched population controls. However, it is 
important to first discuss the benefits of adding population controls. 
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The benefits of added population controls in separate case-control studies to test-positives and test-
negatives  
The importance of having population controls can be seen from Figures 1 and 2, which refer to the 
situation with accompanying persons as controls, and to the more general situation of population 
controls. A comparison of the findings from the test-negative design (TND) with a case-control 
comparison of the test positives with their population controls (CC-POS) and a separate comparison 
of test-negatives with the population (CC-NEG) will enable us to assess which risk factors are specific 
to COVID-19 and which are risk factors for all respiratory infections (including SARS-CoV-2) in 
general. If these studies were all perfect, one would be able to calculate the results of any one 
contrast from the two others, e.g., the results of comparison CC-POS should logically follow from 
combining the results of the TND comparison and CC-NEG (so if the odds ratio for male sex is 1.0 in 
the TND, but is 2.0 in comparison CC-NEG, then it also should be 2.0 in comparison CC-POS). In 
reality there might be differences due to sampling and/or unknown selection biases. Thus, although 
it would be sufficient in theory to only conduct the TND and comparison CC-POS, it is also valuable 
to conduct comparison CC-NEG, which enables us to carry out additional checks for potential biases. 
If data are collected at the time of testing the symptomatic person, data of test-positives, test-
negatives and their population controls will be collected simultaneously. 
This enables ‘triangulation’ [17] with information about specific differences in risk factors between 
symptomatic SARS-CoV-2 infected test-positives and test-negatives with similar signs and symptoms, 
and two matched case-control studies of test-positives and test-negatives with their population 
controls, respectively.  
Accompanying persons as a control group 
Depending on the type of testing facility, many of the persons who go for COVID-19 testing will be 
accompanied by other persons (e.g., drive-thru testing facilities), who may be household members, 
relatives or friends. Thus, it may be expedient to ask an accompanying person to volunteer the same 
information (e.g. completing a questionnaire) at the time of testing the person with symptoms – this 
may in practice be done before the test result is known. These persons are members of the source 
population which generated the cases and should not have COVID-19 symptoms (they may in some 
instances, but in general they should not be accompanying if they do.  Note that for this design it is 
not necessary to carry out the test on the accompanying person (although some studies may offer 
this as an incentive to participate). 
For both the test-positives (COVID-19 cases) and the test-negatives (controls with other respiratory 
infections), the accompanying person can be seen as a matched population control – they may be a 
spouse, sibling or close friend. This approach has been widely used in epidemiology, and the 
strengths and weaknesses have been extensively discussed.[18, 19] Briefly, using friends, siblings or 
spouses as matched population controls, has the advantage of logistic convenience, and may 
indirectly match for various risk factors (e.g. socioeconomic status, availability of health care, health 
seeking behaviour). The case and control will become similar in many respects. As with any other 
pair-matched case-control study, this necessitates a pair-matched analysis – essentially the matched 
analysis focusses on the subgroup of case-control pairs where the case and control differ with 
respect to the exposure under study, i.e. a pair-matched analysis is an analysis of the differences 
that remain between cases and their controls despite them being made more equal by the matching. 
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This strategy leads to two case-control comparisons as represented in Figure1: test-positives with 
their accompanying persons (comparison Case Control-POS in Figure 1), and test-negatives with their 
accompanying persons (comparison Case Control-NEG in Figure 1).  
Comparison CC-POS enables us to study directly the differences in risk factors between a person 
with COVID-19 and a control person without respiratory symptoms. Thus, in this analysis all risk 
factors that increase the risk of COVID-19 (some of which will also be risk factors for other 
respiratory diseases) will be seen to differ between cases and controls. 
Comparison CC-NEG enables us to directly assess risk factors for the mixture of other respiratory 
pathogens (e.g. influenza virus, rhinovirus) that could be causing symptoms similar to those of 
COVID-19. 
Critical reflections on the interpretation of case-control studies with accompanying persons as 
matched controls 
There are potential issues with respect to having accompanying persons as matched controls. The 
use of ‘friend’ controls leaves the choice of the control to the case and not to the investigator [see 
pages 119-120 in[19]] As noted above, friend controls may be quite similar to the cases, which is an 
intended benefit of matching. However, they may have some possible inherent biases [pages 119-20 
in [19]], for example popularity of certain persons, or that extroverts are more often mentioned as 
friends, etc. We should stress that the problem is not that the cases and controls are made too 
similar - this problem applies to all matched case-control studies and is addressed by taking the 
matching into account in the analyses.[18] Rather, the problem is that they may be made similar in 
ways that the investigator cannot control, and certain types of persons might be more valued to be 
named as friends. 
A second issue is that the accompanying persons of the test positives in the CCA comparison may be 
as yet asymptomatic carriers of SARS-CoV-2. A common reflex might be to want to know this and to 
remove these persons from the analysis. However, apart from involving logistically difficult 
additional testing of the accompanying persons, it is not necessary. This is explained in detail in 
APPENDIX B. Briefly, the case-control comparisons focus on symptomatic disease (i.e., COVID-19). 
The studies are based on the source population which would come for testing if they develop 
symptoms; the cases are people who have actually developed symptoms and come for testing. The 
controls should, in theory, be a sample of this source population which generated the cases.[20, 21] 
Since the accompanying persons came with their index person for testing, it is reasonable to assume, 
that they would also have come for testing if they had developed symptoms. This is analogous to the 
use of hospital controls, where the source population is ‘all people who would come to this hospital 
if they developed disease X’ – in this design, the cases are people who actually developed disease X 
and came to the hospital, and the controls are people who came to the hospital for other conditions 
(and therefore would presumably have also come if they had developed disease X).  
Random sampling from country-wide general population health care and other data-bases 
In regions or countries where all health care activities are registered (prescriptions, hospitalizations, 
test-results, etc.) in digital databases, it may be possible to use a completely different type of control 
group, comprising a control population randomly sampled from the region or country as a whole. 
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This is the case in most Scandinavian countries, and regionally in some other countries. While 
analyses based on existing databases may lack the immediacy and flexibility of point-of-care data 
collection of persons who are tested, the advantage is that data are recorded prospectively in past 
time, and the epidemic can be analysed, and re-analysed, in its several stages (e.g., in relation to the 
implementation of social distancing and lock-downs).  
The analysis of the COVID-19 epidemic would start with recorded data of test-positives and test-
negatives for SARS-CoV-2 in the total administrative population of a country or region. Of course, 
one is limited to health care data that are registered at a particular point in time, but one can draw 
on health care data that have been registered before (e.g., pre-existing diseases and prescriptions, 
prior hospitalizations etc.), as well as link other available data such as data on crowding, income, 
level of education, etc., as from socio-economic data-bases. A random population control group 
then is sampled from the same health care and other general databases.  
As a single control group can be used for both CC-POS and CC-NEG (see Figure 2), a potential 
strategy would be to randomly sample several times as many controls as there are test-positives and 
test-negatives combined. For efficiency purposes, the cases and controls, as well as the random 
population control, might be limited to an age bracket, say age 15-74, as there will be few 
symptomatic SARS-C0V-2 cases below age 15, and many persons above age 75 may not be tested 
nor hospitalized. Age and sex matching are undesirable in the context of COVID-19 as these may be 
determinants of infection and disease course.  Moreover, one can always stratify for age and sex, as 
the numbers will be sufficiently large if using registry-based data. Matching on being alive at the 
index date of the cases (i.e. the date of testing) might be considered; however, this might be 
replaced by a control group that is composed of persons being alive in the middle of the months in 
which persons were tested. 
Our description of the possibility of using population health care databases is inspired by a test-
negative case-control study on urinary tract infection with antibiotic resistant bacteria (Extended 
Spectrum Beta Lactamase producing bacteria) in contrast to sensitive bacteria, with added 
population controls to both groups.[10] The experience of combining the test-negative design with 
population-based case-control studies led to better understanding of  the risk factors that are 
specific for infection with resistant bacteria versus general risk factors for urinary tract infections. 
For example, male gender proved a strong risk factor for antibiotic resistance in the test-negative 
design study, while female gender was a strong risk factor for urinary tract infections in general, 
because men generally only acquire urinary tract infections at older ages, subsequent to prostate or 
other pathology which puts them also at risk of acquiring resistant bacteria in hospitals.[10]   
 Other population control groups 
Many alternatives for population control selection are possible in principle, depending on the 
situation in different regions or countries. Some of these other options will be closer to the flexibility 
of the ‘accompanying persons’ control groups, others will be closer to the advantages of using 
existing databases. The appropriate approach will depend strongly on the databases available, the 
type of health care, and other local considerations. For example: 
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- records from General Practitioner databases (e.g., in the UK, in some regions in Italy or Spain), or 
third-party payers and insurers (Medicare, Medicaid, health maintenance organizations in the US), 
which will also allow for database-centered research. 
- if patients are presenting in a special set-up organized by groups of General Practitioners (e.g., 
“Corona-tents” managed by several GP practices where patients are referred to for testing), control 
persons may  be a sample from these general practices; this sample could be matched to the 
practice of the referring GPs, or alternatively weighted according to the size of the referring GP 
practices. This might facilitate the collection of specific new information relevant to local situations 
in individual practices (e.g., the use of local swimming facilities). 
- if patients present to outpatient clinics or hospital departments, a control group of non-respiratory 
out- or inpatients might be constructed to represent the catchment population of the hospital; such 
patient controls used to be common in pharmacoepidemiology.[22] 
Critical reflections on the choice of population controls 
Apart from the different possibilities in different countries or regions, it is imperative to consider to 
what extent the test-positives and test-negatives from a TND are representative of all cases in the 
general population, i.e., whether the general population can really be seen as the source population 
for the tested persons. There are two considerations: about patient selection and doctor’s 
preferences.  
Patient selection 
Not all diseases present equally to health care facilities. In countries with universal access to health 
care and relatively standardized care, it is likely that, for example, almost all solid cancers (colon, 
lung, etc.) with onset before age 70 will ultimately be diagnosed and recorded. That is not the case 
for self-limiting diseases such as influenza-like illnesses or headache. Many persons will just stay 
home. Only persons who worry or have more severe symptoms will present themselves to a primary 
care service. Still, in a country with universal access and standardized care, the types of person who 
present themselves will roughly be similar, and if testing is done for SARS-CoV-2, test-positives and 
test-negatives can be seen as drawn from the same underlying general population. The type of 
person that is tested may differ between countries, however. During the recent COVID-19 epidemic, 
testing for persons with minor symptoms was available in Germany; in the Netherlands only persons 
with symptoms that were sufficiently severe to be hospitalized were tested. Because these were 
country-wide measures, in both countries the general population may be seen as the source 
population. In this context, it should be noted that if (self) selection is based only on severity of 
disease, this will not create a bias in itself – it is fine just to study ‘symptomatic disease’, and we can 
identify risk factors for this. Problems only arise if there are other factors which affect presentation 
for testing, given a particular level of symptoms. 
For example, consider private health care facilities that are only accessible to individuals who can 
afford them (these facilities exist in many guises: from standard private health care coming as an 
employee benefit to facilities only available to the very rich). A comparison of the test-positives and 
test-negatives from such facilities with a general population control group may not be warranted, 
because of inherent differences in socio-economic status, medical care, and life style. Among 
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persons with testing in private facilities, both test positives and test negatives are for example 
unlikely to live in very overcrowded conditions. Thus, a better control group, representing their own 
source population, might be composed of other person (or patients) who make use of the same 
health care facilities. This means that one may not be able to study all of the causes of the disease 
(e.g. if poverty is an underlying cause, but no one who accesses these health care facilities is low-
income). Also, if we suspect that there are differences in access to testing for persons with very mild 
symptoms or without symptoms (depending on type or health insurance or wealth), but few such 
differences for severe disease, then one might restrict the analysis to the subgroup of tested 
individuals with more severe symptomatic disease. 
Doctors’preferences 
Even in settings with relatively standardized care, there might be variation in testing strategies for a 
new disease like COVID-19 between primary care practices. The existence of physician preference in 
general has been studied internationally,[23] and can be based on a different interpretation of the 
literature on topics where there is not yet consensus, or even to implicit biases (regarding age, sex, 
ethnicity). If this is suspected to have been the case, it might be better to select general population 
controls from the GP practices of the individuals who underwent testing – and to approach this in 
the analysis as a form of ‘matching’.  Matching by GP practice would, however, limit the ability to 
compare between catchment areas and lead to loss of information about regional differences. Once 
again, restricting the analysis to patients with severe disease (whether test-positive or test-
negative), may suffer less from self-selection and testing preference by doctors. An analysis 
according to severity can also be added as a sensitivity analysis. 
 
Discussion  
An ideal approach for identifying risk factors for COVID-19 would involve random/representative 
population sampling.[3] However, in the surveillance efforts that are being developed when an 
epidemic is unfolding, population-based testing often is limited by laboratory capacity (i.e., due to 
unprecedented demands for reagents and trained technicians), funding and political will. The first 
thoughts of decision makers are to facilitate testing for people with symptoms who became ill 
recently, either in order to isolate, or in order to know which treatment trajectory is necessary if 
symptoms worsen.[1, 2] This is what is being done by facilitating the availability of tests to general 
practitioners, by ‘drive-thru’ testing, testing at pharmacies, etc. 
The situation with COVID-19 remains urgent, and it is important that the best possible use is made of 
information collected in the process of widespread testing of symptomatic persons. Therefore, there 
may be research and public health benefits in employing a test-negative case-control design 
preferably combined with case-control studies with population controls added to it. Still, such 
collection of information has to be as ‘light’ as possible, in order not to disturb the primary medical 
aim: to test people for their own benefit and for controlling the epidemic. This proposed data 
collection can be done with minimal extra effort, it would roll along with the epidemic, and can 
potentially yield important information at much less cost, and with greater ease, than doing 
genuinely random population repeated sampling and testing. In situations where extensive data 
bases exist, data were collected as the epidemic unfolded, and then kept frozen in time in the data-
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bases. This allows to return to the data, and evaluate the course of the epidemic with new 
hypotheses.  
Adding general population controls yields three linked case-control studies (the TND, CC-POS and 
CC-NEG) and creates a triangulation situation[17] for inferences about local as well as general factors 
that drive the pandemic. Likewise, any follow-up or testing ‘add-ons’ will lead to better 
understanding. Finally, having the infrastructure for a test-negative design already established in 
different settings may be a valuable base to evaluate the effectiveness of interventions such 
vaccines when they become available, or other measures to limit transmission (e.g. use of face 
masks). Public health authorities should urgently consider setting up formal test-negative case-
control studies and case-control studies with population controls, to learn more about the risk 
factors for symptomatic SARS-CoV-2 infection in the COVID-19 pandemic.  
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Figure 1: Test-negative design and case-control studies with accompanying persons 
 
 
Figure 2: Test-negative design and case-control studies with random population controls 
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Appendix A: Assumptions that underly generalizability of estimates of a Test-Negative Designs to a 
broader population 
The TND design has been described in detail in numerous papers. In a recent paper two of the 
authors of the present paper presented this study design as a variant of ‘case-control studies with 
other disease controls’. [8] These include hospital-based case -control studies in which the cases are 
identified through a particular health-care facility, and the controls are other patients at the same 
health-care facility.  
Case-control studies with diseased controls have a long history in epidemiology, from the first case-
control studies of smoking and lung cancer (where lung cancer patients were compared to other 
patients of the same wards), to several applications in pharmacoepidemiology,[22] and applications 
in cancer registries.[24] Such studies are recognized as having produced some major and valid 
findings, such as the association between smoking and lung cancer.[25] However, they rest upon the 
assumption that the main risk factor under study does not cause the ‘other diseases’ which are used 
as controls.  
The main difference between the TND in general and other case-control studies with diseased 
controls is that in the TND the cases and controls are persons with similar signs and symptoms, but 
who ‘test’ differently on a crucial test for a particular disease. As such, the controls (those who test 
negative) will usually have another disease with similar signs and symptoms to the disease under 
study. 
This means that in the particular context of the application of the TND to risk factors for COVID-19, 
the standard assumption of the hospital-based case-control study, that the exposure of interest is 
not a cause of the other disease, is not true for many exposures. The other diseases will mainly be 
other respiratory infections, and several of their risk factors will be similar to those for COVID-19. As 
mentioned in the paper, the TND will not detect risk factors that are of equal strength for COVID-19 
and the diseases of the controls; however, it will detect differences in magnitude of a particular risk 
factor (say, crowding), or risk factors that would be totally specific for COVID-19. This situation is 
similar to the situation of another TND on urinary tract infection with antibiotic resistant bacteria 
(Extended Spectrum Beta Lactamase producing bacteria) in contrast to sensitive bacteria, with 
added population controls to both groups.[10] In that study, recent hospitalizations proved to be a 
risk factor that was specific for acquiring infections with resistant bacteria; other findings could only 
be interpreted by combining the TND with the population controls (e.g., the effect of maleness 
which was a strong positive risk factor in the TND analysis, but the inverse was true in the 
comparison with the population).  
The basic question is whether the OR generated by a TND, for a factor that is a risk factor for the 
disease of interest and not for the control diseases, can in principle be the same as the OR that 
would have been generated by a population-based case-control design. This question has either 
been answered with strong doubts by some[26] because the TND does not have a well-defined 
underlying source population; others have answered it positively, some with a few qualifications;[4, 
7, 27] some with more qualifications.[9] In essence, we agree with the affirmative answer to that 
question because the TND permits a positive answer to one ‘sentinel question’ about the validity of 
a control group: would this person, who does not have the disease, have presented him/herself for 
testing in that same facility if s/he would have had the disease under study.[8] The answer for a TND 
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is obviously positive. As a minimum, the results of the TND are valid for the population of ‘the 
tested’.  
An additional subtlety is that in a sense, one might even state that in exceptional circumstances 
where the inclination to be tested is highly linked to characteristics of the tested person, or to 
suspicions or habits of doctors who serve a particular segment of the population, the standard case-
control study with ‘test-positive cases’ and random general population controls could produce 
wrong answers, since the type of persons going for testing at particular medical facilities might be 
self-selected in a way that the random sample of the underlying population is not. [If they were 
billionaires with doctors catering for that category of persons, there would be habits that would not 
differ from other billionaires but might differ quite a lot from the general population]. The TND 
remedies that situation by its design by choosing controls with the same selection pressures, and will 
in such circumstances produce a valid answer for the tested.  
The next question is whether the OR for the TND (= those who go for testing) is applicable to the 
general population from which it is drawn, or for other populations, again for risk factors that are 
not known risk factors for the control diseases. It is possible that the TND may deliver unbiased odds 
ratios for the source population of the ‘tested’ (i.e. everyone who would have been tested if they 
had developed symptoms), but these findings may not be completely ‘transportable’ to the wider 
general population or other populations – for example, the effect might be higher among the tested 
than among the general population. However, there would only be lack of generalizability if there 
were strong effect modification, and the distribution of effect modifiers was markedly different in 
other populations.[28]  
For example, is it possible that a genetic a risk factor for Covid-19 is found in a TND study, but not in 
the wider population? This seems unlikely. More importantly, these issues of generalizability to 
other populations is an issue in many case-control studies, and is not unique to the TND. For 
example, one might ask whether the original studies on smoking and lung cancer in (white Anglo-
Saxon) male British doctors in the 1960s would be equally applicable to lawyers, actors, sewage 
cleaners, or to woman and non-white non-Anglo-Saxon persons in general. Issues of generalization 
apply to all case-control study findings, not just the TND. 
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APPENDIX B. Sensitivity analysis: quantification of misclassification bias in TND due to false test-
negatives and false test-positives 
If one assumes particular values of Sn, Sp in a particular study, then one can estimate the bias that is 
introduced by misclassification of the disease. This can be used to do a sensitivity analysis where we 
assume a range of possible values of Sn, and Sp. In theory, one can then do an adjustment. However, 
given the uncertainties involved, such corrections are usually conducted as additions to the main 
analysis (which would report the unadjusted associations as the main results but also mention the 
sensitivity analysis findings), rather than substitutes for it. 
This Appendix will explain first the situation of disease misclassification in a TND study that is 
intended to contrast COVID-19 patients vs. patients with other respiratory disorders (mostly other 
viral infections); second it will explain how different proportions of COVID-19 vs. other respiratory 
disorders will influence the role of sensitivity and specificity; and thirdly, that it is possible to 
calculate back from an observed 2x2 table to the ‘true’ table, given assumptions on sensitivity and 
specificity. 
One may start from the assumption that the specificity of the RT-PCR is very high, except for 
mishandling of specimens, mishandling of test information (mixing up of persons), or batch 
contamination. In contrast, the sensitivity may depend on several factors such as the severity and 
duration of the disease, the way the sample was obtained, as well as the performance of the test 
itself (See paper). 
To see what might happen in the TND situation, a simple numerical example is useful. All persons 
with COVID-19 with a number of characteristics (a certain degree of symptoms, and a certain degree 
of worry, personality, access to health care etc.), will have presented themselves to a particular test 
facility. If only 70% of them will test positive (sensitivity is 70%), the remaining 30% will be false-
negatives, but as they have all presented themselves, they will be classified as test-negatives along 
with the group of true test-negatives, i.e. persons with other respiratory diseases. If we assume that 
the number of false-positives is negligible, and suppose that at a particular test-site there are 70 
test-positives and 150 test negatives, then the true number of COVID-19 patients will be 70/0.7 = 
100. This means that 30 of the 150 test-negatives are actually false-negatives, which is 20%. There 
will thus be 100 COVID-19 patients out of 220 tested. Thus, all ORs on the observed numbers will be 
biased towards the null. In principle, we can recalculate the true OR without test misclassification by 
a standard procedure that surmises that the false-negatives amongst the test-negatives should have 
the same exposure frequencies as the test-positives (i.e. misclassification is non-differential).1 
In this example, we have not yet taken into account that a (probably small) number of the test-
positives are actually false-positives, which in this numerical example is negligible, but that is not 
 
1 Suppose that 42 of test-positives were men (60%), and only 50% of test negatives were men, this yields an OR for 
maleness of 1.5.  The real percentage of males amongst the true test-negatives can be calculated as ‘X’ in the equation: 
0.50 = (0.8 x X) + (0.2 x 0.60), which gives an X of 0.475. Then the true odds ratio becomes: (0.60 x 0.525)/(0.475 x 0.40) = 
1.66 (rounded off).  
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always the case, as this depends on the proportion of true COVID-19 patients among the persons 
tested.   
To demonstrates what happens with mutual misclassification, in different scenarios of prevalence of 
COVID-19 relative to prevalence of other respiratory disorders amongst the persons tested, we can 
make Table 1, following a reasoning similar to that by Flegal et al.[29] From Table 1 it becomes 
apparent that if the prevalence of current COVID-19 infection is high relative to the prevalence of 
other respiratory viral diseases amongst the tested (say, in summer months at the peak of an 
epidemic in a population without immunity), the main driver of the misclassification is the sensitivity 
of the test: a large proportion of test-negatives might actually be false negatives. Inversely, in the 
situation of an almost disappearing epidemic in winter months (say, when a vaccine would be 
available and it would be winter), the number of test-positives that would actually be false-positives 
will become quite large, i.e., the specificity becomes more important. In each of these extreme 
situations, there is misclassification, but it is less severe in the latter instances (sporadic COVID-19).  
It is possible to make approximate assumptions about the ratio of the estimated OR to the true OR, 
based on tables like this, with appropriate estimates of sensitivity and specificity and relative 
prevalences of non-Covid-19 respiratory diseases amongst the tested.  
TABLE 1: Variation of observed OR for different True COVID-19 percentages amongst the tested 
with the same sensitivity, specificity, and the same exposure frequency in true test-negatives 
(assumed to be 50%), and same true underlying OR of 2.0. 
Fraction 
TRUE 
COVID-19  
SENS SPEC TRUE Odds 
Ratio  
(rounded) 
OBSERVED 
Odds 
Ratio 
(rounded) 
0,97 0,70 0,99 2,00 1,07 
0,90 0,70 0,99 2,00 1,21 
0,50 0,70 0,99 2,00 1,69 
0,10 0,70 0,99 2,00 1,80 
0,03 0,70 0,99 2,00 1,58 
 
Finally, there is the possibility to calculate back from an observed 2x2 table to the “true” 2x2 table, 
given assumptions on sensitivity and specificity. See Chapter 6 on “Outcome misclassification in Lash 
et al.[15] This “correction”, is based on a single observed 2x2 table, when there has been confounder 
adjustment, the adjusted odds ratio will differ from the crude odds ratio, and therefore one cannot 
use the crude 2x2 table for the “correction” – more complex methods are available if one wishes to 
also correct for confounders while “correcting” for misclassification.[16] 
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APPENDIX C: Reason for not omitting controls that are asymptomatic carriers of SARS-CoV-2 
This reasons for not omitting controls that are asymptomatic carriers of SARS-CoV-2 can be 
illustrated by considering a hypothetical study. Suppose we could identify the population (a 
subgroup of the general population) which would come for testing if they had symptoms. Ideally, 
one would then test all of this population and we would estimate the risk of infection in this 
population, and in various subgroups. In the population (P) there might be a certain number of 
people (T) who tested positive. Note that the population denominator (P) includes both people who 
currently have symptomatic infections and people who don’t – it is just the total population ‘at risk’. 
The risk of having a symptomatic infection is then T/P. If we compare two subgroups who are 
exposed or not-exposed to a particular factor, their risks might be T1/P1 and T0/P0 respectively, and 
the risk ratio (the ratio of these two proportions) would indicate the relative risk of symptomatic 
Covid-19 infection in the exposed and non-exposed (e.g. if the RR was 2.0 then the exposed would 
be twice as likely as the non-exposed to have symptomatic Covid-19 infection).  
A case-control study involves studying all of the ’cases’ (i.e. T) and a sample of the population which 
generated them (P). Thus, provided that the controls are a representative sample of the source 
population P (i.e. everyone who would have come for testing if they had symptoms – which is a 
reasonable assumption to make since they came with someone who was being tested), then the 
odds ratio for Covid-19 infection in the case-control study will estimate the risk ratio in the 
population (P) which generated the cases (T). Of course, a small number of the controls may have 
asymptomatic Covid-19 infection, and would have tested positive if they had been tested. But this is 
not a problem – they would have been part of the denominator (P) if a full population survey had 
been conducted, and they are therefore eligible to be selected as controls. This is analogous to the 
case-cohort (case-base) design which is a commonly used design for case-control studies .[21, 30] 
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